Stocktoria
DiaSorin S.p.A. DIA.MI
DiaSorin S.p.A. (DIA.MI) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.85% (safety: moderate). FY2025 revenue was €1.2B at a 13.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Healthcare · percentile among 79 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.097 |
| Retained earnings / assets | 0.054 |
| EBIT / assets | 0.094 |
| Equity / liabilities | 1.222 |
About DiaSorin S.p.A.
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
FAQ
Is DIA.MI financially healthy?
DiaSorin S.p.A.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DIA.MI pay a dividend, and is it safe?
Yes. DiaSorin S.p.A. pays a dividend yielding about 1.85% with a 40.8% payout ratio, rated “moderate” for safety.
How profitable is DIA.MI?
In FY2025, DiaSorin S.p.A. had a net margin of 13.0% and a return on equity of 9.8%.
Is DIA.MI overvalued or undervalued?
DiaSorin S.p.A. trades at about 24.5× trailing earnings — below its 10-year norm (10-year range 25.5×–29.9×, median 29.8×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for DIA.MI?
The average Wall-Street price target for DiaSorin S.p.A. is €70.52, about 1.6% above the recent price, from 14 analysts (consensus: hold).
Is DIA.MI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DiaSorin S.p.A.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 22.1×, a dividend yield of 1.85%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · IT · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.